Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women

Phase 4

Completed

• Conditions: Menopause; Hypertension

• Registration Number: NCT00147524
• Lead Sponsor: Pfizer

Brief Summary

ACE inhibitors are thought to modify the endothelium in a number of ways. Quinapril is an effective and well-tolerated ACE-I for the treatment of patients with hypertension and congestive heart failure. Quinapril produces favourable haemodynamic changes and improves ventricular and endothelial function in patients with various cardiovascular disorders. These effects are mediated through the binding of quinaprilat to both tissue and plasma-ACE.

Quinapril 10 to 40 mg once daily improved endothelial function (as measured by improved FMD or reduced vasoconstrictive/increased vasodilative response to Ach) in patients with CAD and hypertension over 2 to 6 months of therapy; improved endothelial function was also observed in patients with CHF receiving a single infusion of quinaprilat. In general, quinapril showed neutral or beneficial effects on lipid profiles, glycaemia and renal haemodynamics. (3) There are no data available considering effects of quinapril on endothelial dysfunction in post- menopausal woman with mild to moderate hypertension and with pathological endothelial function.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-10
• Study Completion: 2005-05
• Study First Submitted: 2005-09-02
• Study First Submitted QC: 2005-09-02
• Study First Posted: 2005-09-07
• Status Verified: 2007-04
• Last Update Submitted: 2007-04-26
• Last Update Posted: 2007-04-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 70

Inclusion Criteria

• pathological baseline FMD (< 5%) at screening
• women in post-menopause at least for 2 years (post-menopausal defined as having amenorrhea for Å' 2 years)
• mild or moderate hypertension (BP > 140/90 mmHg)

Exclusion Criteria

• uncontrolled severe hypertension (BP > 180/110 mmHg)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
To evaluate the effect of 10, 20 and 40 mg daily sequential quinapril doses in a 3 x 8 weeks treatment period as changes to baseline pathological FMD.

Secondary Outcome Measures

Name	Time	Method
1.In a subgroup of about 30 patients to assess microvascular vasomotor function by laser Doppler (LD) techniques. For all patients: 2.Evaluation of changes of BP parameters. 3.Changes in PAI-1 level. 4.Collect safety data.

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇭🇺 Szombathely, Hungary